A phase 3, multicenter, double blind, placebo-controlled, randomized withdrawal trial to evaluate the efficacy, safety, and phar

A phase 3, multicenter, double blind, placebo-controlled, randomized withdrawal trial to evaluate the efficacy, safety, and pharmacokinetics of deucravacitinib in children and adolescents from 5 to less than 18 years of age with active juvenile psoriatic arthritis

Abierta

Código protocolo: IM011-1071
Código EudraCT: No aplica
Grupo de investigación: Reumatología
Servicio: Reumatología
Investigador/a principal: Lopez Corbeto, Mireia
Patología: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
Fase: Fase III